What is Zacks Small Cap’s Forecast for ABEO Q1 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Zacks Small Cap issued their Q1 2025 earnings per share estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will earn ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.33) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.19.

ABEO has been the topic of a number of other research reports. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Oppenheimer began coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Abeona Therapeutics has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $4.99 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market capitalization of $216.92 million, a P/E ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The company’s 50-day moving average is $5.43 and its 200 day moving average is $5.82.

Institutional Trading of Abeona Therapeutics

A number of large investors have recently modified their holdings of the company. Wellington Management Group LLP bought a new stake in Abeona Therapeutics during the 4th quarter valued at $520,000. Western Standard LLC increased its stake in shares of Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $67,000. Twinbeech Capital LP bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $58,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Abeona Therapeutics in the fourth quarter worth about $362,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.